Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo

BMC Cancer volume 16, Article number: 702 (2016) Cite this article

Abstract

Background

Iron is essential for cell replication, metabolism and growth. Because neoplastic cells have high iron requirements due to their rapid proliferation, iron depletion may be a novel therapeutic strategy for cancer. Deferasirox (DFX), a novel oral iron chelator, has been successful in clinical trials in iron-overload patients and has been expected to become an anticancer agent. However, no studies have investigated the effects of DFX on pancreatic cancer. This study aimed to elucidate the effects of DFX against pancreatic cancer.

Methods

The effects of DFX on cell cycle, proliferation, and apoptosis were examined in three human pancreatic cancer cell lines: BxPC-3, HPAF-II, and Panc 10.05. The effect of orally administered DFX on the growth of BxPC-3 pancreatic cancer xenografts was also examined in nude mice. Additionally, microarray analysis was performed using tumors excised from xenografts.

Results

DFX inhibited pancreatic cancer cell proliferation in a dose-dependent manner. A concentration of 10 μM DFX arrested the cell cycle in S phase, whereas 50 and 100 μM DFX induced apoptosis. In nude mice, orally administered DFX at 160 and 200 mg/kg suppressed xenograft tumor growth with no serious side effects (n = 5; average tumor volumes of 674 mm3 for controls vs. 327 mm3 for 160 mg/kg DFX, p <0.05; average tumor volumes of 674 mm3 for controls vs. 274 mm3 for 200 mg/kg DFX, p <0.05). Importantly, serum biochemistry analysis indicated that serum levels of ferritin were significantly decreased by the oral administration of 160 or 200 mg/kg DFX (n = 5; average serum ferritin of 18 ng/ml for controls vs. 9 ng/ml for 160 mg/kg DFX, p <0.05; average serum ferritin of 18 ng/ml for controls vs. 10 ng/ml for 200 mg/kg DFX, p <0.05). Gene expression analysis revealed that most genes in pancreatic adenocarcinoma signaling, especially transforming growth factor-ß1 (TGF-ß1), were downregulated by DFX.

Conclusions

DFX has potential as a therapeutic agent for pancreatic cancer. Iron depletion was essential for the antiproliferative effect of DFX in a preclinical model, and DFX acted through the suppression of TGF-ß signaling.

Peer Review reports

Background

Pancreatic cancer is the fifth leading cause of cancer-related deaths, and the number of cases has been increasing in Japan [1]. It is the fifth and fourth leading cause of cancer-related deaths in Europe and in North America, respectively [2]. Pancreatic cancer is associated with the worst prognosis among solid tumors [3]; the 5-year survival rate of pancreatic cancer, including resectable cases, is not more than 10 % [4]. Surgical resection is the only potential curative therapy, but many patients with pancreatic cancer are not candidates for surgical resection at the time of diagnosis. For patients with unresectable pancreatic cancer, chemotherapy is recommended as the current standard care [5]. During the last two decades, gemcitabine has been the standard chemotherapy for pancreatic cancer. Recently, new combination chemotherapies have been developed, such as regimens combining fluorouracil, irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX) or albumin-bound paclitaxel with gemcitabine [6, 7]. However, while combination chemotherapies have shown therapeutic advantages over single-agent gemcitabine, they also have a high incidence of side effects. In addition, more than half of pancreatic cancer patients are diagnosed at an age of 65 years or older [4]. Therefore, a new chemotherapeutic strategy for pancreatic cancer is required for these patients with refractory chemotherapy due to side effects and/or advanced age.

Iron is essential for cell replication, metabolism and growth [8]. Because neoplastic cells have high iron requirements due to their rapid proliferation, iron depletion could be a novel therapeutic strategy for cancer [9]. Although iron chelators, which are commonly used for treating iron-overload disease, are not classified as anticancer drugs; they exert antiproliferative effects in several cancers [10–12]. We have reported that deferoxamine (DFO), a standard iron chelator, can prevent the development of liver preneoplastic lesions in rats [13]. We also performed a pilot study using DFO in advanced hepatocellular carcinoma patients and reported the efficacy of this iron chelator [14]. Considering the mechanism of action of iron chelators as anticancer agents, as well as other cancers, iron chelators are thought to be effective pancreatic cancer treatments. Kovacevic et al. reported that thiosemicarbazone iron chelators inhibited pancreatic cancer growth in vitro and in vivo [15]. Therefore, iron chelators represent a potential therapeutic strategy for pancreatic cancer. However, most iron chelators, including DFO and thiosemicarbazones, cannot be administered orally, thus limiting their clinical application.

Recently, deferasirox (DFX), a newly developed oral iron chelator, was successful in clinical trials in iron-overload disease patients and has been implemented as an alternative to DFO [16]. A number of in vitro and in vivo studies have demonstrated that DFX has powerful antiproliferative effects [17]. To our knowledge, there have been no studies investigating the effects of DFX against pancreatic cancer. Therefore, this study aimed to evaluate the antiproliferative activity of DFX against pancreatic cancer in vitro and in vivo.

Methods

Cell culture

The pancreatic cancer cell lines BxPC-3, HPAF-II, and Panc 10.05 were obtained from the American Type Culture Collection (Manassas, VA, USA). BxPC-3 and Panc 10.05 cells are epithelial cell lines that were derived from pancreatic adenocarcinomas. The HPAF-II cell line consists of epithelial cells derived from ascites that originated from pancreatic adenocarcinomas.

BxPC-3 cells were grown in RPMI-1640 (Life Technologies, Carlsbad, CA, USA) with 10 % (v/v) fetal calf serum. HPAF-II cells were grown in Eagle’s medium (Life Technologies) with 10 % (v/v) fetal calf serum. Panc 10.05 cells were grown in RPMI-1640 (Life Technologies) containing 10 units/ml of human recombinant insulin, and 15 % (v/v) fetal calf serum. All media were supplemented with 50 μg/ml gentamicin. All cells were incubated at 37 °C in a humidified atmosphere containing 5 % CO2.

Reagents

The oral iron chelator DFX was obtained from Novartis (Basel, Switzerland). For in vitro studies, DFX was dissolved in dimethyl sulfoxide at a stock concentration of 100 mM and was used at the concentrations indicated in the results and figures by dilution in culture media containing 10 % fetal calf serum. For in vivo studies, DFX was dissolved in sodium chloride solution (0.9 % w/v; Chemix Inc., Shinyokohama Kohoku-ku, Yokohama, Japan).

Cell proliferation

Cellular proliferation was examined using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. Cell suspensions (2,000 cells/100 μl) were added to each well in a 96-multiwell culture plate (BD Bioscience, San Jose, CA, USA) and incubated at 37 °C for 24 h. The indicated concentrations of DFX were then added to each well, and the cells were incubated for a further 72 h. At the end of the culture period, 10 μl of MTS solution (Promega, Madison, WI, USA) was added to each 100 μl of culture media and incubated for 2 h. Absorbance at 490 nm was measured with a multimode reader (Infinite 200 PRO, Tecan Trading, AG, Switzerland), and the results are expressed as the percentage viable with respect to the untreated control.

Cell cycle analysis

Each pancreatic cancer cell line was seeded into 100-mm dishes and cultured with phosphate-buffered saline (PBS) as a vehicle control or DFX at 10, 50, or 100 μM for 72 h. After incubation, the cells were fixed with 70 % ethanol and stored overnight at −20 °C. The cells were washed and then stained with a solution containing 0.1 % Triton® X-100 (Promega), 0.02 mg/ml propidium iodide (PI; Sigma-Aldrich, St. Louis, MO, USA), and 0.2 mg/ml RNase A (Qiagen, Hilden, Germany) in the dark at 37 °C for 15 min. After staining, the cells were subjected to cellular DNA content examination by a flow cytometer (Gallios, Beckman Coulter, Fullerton, CA, USA). The data were analyzed by Multicycle for Windows software (Beckman Coulter).

Apoptosis analysis by flow cytometry

For the apoptosis analysis, the cells were cultured as described above. After harvesting, apoptosis was evaluated with an apoptosis detection kit (Annexin V Apoptosis Detection Kit APC, eBioscience, San Diego, CA, USA) according to the manufacturer’s instructions. After staining, the cells were examined using a flow cytometer (Gallios, Beckman Coulter). The data were analyzed by FlowJo software (Tree star, Ashland, OR, USA).

Apoptosis analysis with the luminescence assay

Cell suspensions (2,000 cells/100 μl) were added to each well of a 96-multiwell culture plate (BD Bioscience) and were incubated at 37 °C for 24 h. PBS as a vehicle control or the indicated concentrations of DFX were then added to each well, and the cells were further incubated for 48 h. Immediately after the incubation, caspase activity was measured using the caspase 3/7 assay kit (Caspase-Glo 3/7 kit, Promega) according to the manufacturer’s instructions.

Tumor xenografts in nude mice and deferasirox administration

Animal care was performed in accordance with the animal ethics requirements at Yamaguchi University School of Medicine, and the experimental protocol was approved (approval ID 21-035). Twenty female BALB/c (nu/nu) mice were purchased from Nippon SLC (Shizuoka, Japan) and were housed in sterile conditions. Experiments commenced when the mice were 8–10 weeks of age. Tumor cells (BxPC-3) in culture were harvested and resuspended in a 1:1 ratio of RPMI-1640 and Matrigel (BD Bioscience). Viable cells (5 × 106 cells) were injected subcutaneously into the backs of the mice. After engraftment, tumor size was measured using Vernier calipers every 2 days, and tumor volume was calculated as follows: tumor volume (mm3) = (the longest diameter) (mm) × (the shortest diameter) (mm)/2. When tumor volumes reached 150 mm3, oral treatment began (day 0). Each group of mice (n = 5) received DFX suspended in saline, which was administered by oral gavage every second day, with three treatments per week, over 21 days at concentrations of 120, 160, or 200 mg/kg. The control mice were treated with the vehicle alone. At the end of the experiment, the mice were sacrificed, and the tumors were excised and processed for immunohistochemistry and genetic analyses. A total of 20 blood samples were collected simultaneously during tumor removal. Serum levels of ferritin were measured using the enzyme-linked immunoassay method (Mouse Ferritin ELISA kit, Kamiya Biochemical Company, Seattle, WA, USA). Serum biochemistry with the exception of ferritin was analyzed by YAMAGUCHI Laboratory Co., Ltd. (Ube, Japan).

Immunohistochemistry

The removed tumors were fixed in 4 % paraformaldehyde (Muto-kagaku, Tokyo, Japan), sectioned, and embedded in paraffin. Immunohistochemistry was performed as previously described on the paraffin sections with antibody specific to ferritin-H (Anti-Ferritin Heavy Chain antibody, AbCam, Cambridge, MA, USA) [18]. The slides were scored according to the intensity of the immunoreactivity and the percentage of epithelial cells stained [19].

The detection of gene expression alternation in resected tumors induced by deferasirox administration

Total RNA isolation

A total of six tumors were genetically analyzed. Of these, three tumors were removed from vehicle-treated mice, and the other three tumors were removed from DFX 200 mg/kg-treated mice. According to the manufacturer’s instructions, total RNA was isolated from the removal tumors using TRIzol Reagent (Invitrogen Corp., CA, USA) and purified using the SV Total RNA Isolation System (Promega). RNA samples were quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA), and RNA quality was checked using an Experion automated electrophoresis station (Bio-Rad Laboratories Inc., Hercules, CA, USA).

Gene expression microarrays

The cRNA was amplified, labeled, and hybridized to a 60K Agilent 60-mer oligomicroarray according to the manufacturer’s instructions. All hybridized microarray slides were scanned by an Agilent scanner. Relative hybridization intensities and background hybridization values were calculated using Agilent Feature Extraction Software (9.5.1.1).

Data analysis and filter criteria

The raw signal intensities of all samples were log2-transformed and normalized with a quantile algorithm from the ‘preprocessCore’ library package [20] on Bioconductor software [21]. We selected the probes, excluding the control probes, where the detection p-values of all samples were less than 0.05, and used them to identify differentially expressed genes. To determine significant enrichment canonical pathways, we used the tools and data provide by the Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, INC. http://www.ingenuity.com). The results are the comparisons of tumors removed from vehicle-treated mice vs. the tumors removed from DFX 200 mg/kg-treated mice.

Statistical analyses

All obtained data are calculated and expressed as the mean ± SD. In the in vitro experiments, the differences were analyzed statistically using 1-way ANOVA, followed by Dannett’s test. In the in vivo experiments, the differences were analyzed statistically using the Kruskal-Wallis H test, followed by Steel’s test. JMP 9 statistical software (SAS Institute Inc., Cary, NC, USA) was used in the analysis. Values of p <0.05 were considered significant.

Results

DFX inhibited cell proliferation in pancreatic cancer cell lines

To examine the antiproliferative activity of DFX against pancreatic cancer in vitro, the pancreatic cancer cell lines BxPC-3, HPAF-II, and Panc 10.05 were incubated with either vehicle control (PBS) or the indicated concentrations of DFX for 72 h; then, the cell survival rates were measured using the MTS assay. The cell survival rates are shown in Fig. 1. Incubation of all three cell lines with DFX inhibited cellular proliferation in a dose-dependent manner. DFX had the same level of antiproliferative activity in all three cell lines. As indicated in Table 1, the IC50 values for the BxPC-3, HPAF-II, and Panc 10.05 pancreatic cancer cell lines were 7.3 ± 1.0, 5.6 ± 1.0, and 6.1 ± 0.2 μM, respectively. There were no significant differences in the IC50 values of each pancreatic cancer cell line.

Fig. 1
figure 1

DFX inhibited the proliferation of pancreatic cancer cell lines. Cell proliferation was measured using the MTS assay after cells were treated with DFX 72 h. The viability of BxPC-3, HPAF-II, and Panc 10.05 cells incubated with DFX decreased in a dose-dependent manner. The data are presented as the mean ± SD (n = 3–5). *p <0.05, **p <0.01 vs. control

Full size image
Table 1 IC50 values of DFX in three pancreatic cancer cell lines after a 72-h incubation
Full size table

DFX arrested the cell cycle at the S phase in pancreatic cancer cell lines

To explore the mechanism of the antiproliferative activity of DFX, the pancreatic cancer cell lines BxPC-3, HPAF-II, and Panc 10.0 were incubated with either the vehicle control (PBS) or 10, 50, or 100 μM concentrations of DFX for 72 h, and the cell cycle was examined with flow cytometry using PI staining. The analyzed results are shown in Fig. 2a, and the percentage of S phase cells are highlighted in pink. The percentage of S phase cells for each concentration of DFX is shown in Fig. 2b. In all three cell lines, the percentage of S phase cells incubated with 10 μM concentration of DFX was increased. These results demonstrated that 10 μM DFX arrested the cell cycle of pancreatic cancer cells in S phase.

Fig. 2
figure 2

DFX arrested the cell cycle at the S phase in pancreatic cancer cell lines. a BxPC-3, HPAF-II, and Panc 10.05 cells were incubated with the vehicle control (PBS) or DFX at concentrations of 10, 50, or 100 μM for 72 h. The cell cycle phase of the treated cells was examined by flow cytometry. The percentages of S phase cells are highlighted in pink. b The percentages of S phase cells in each concentration of DFX are shown. When the cells were treated with 10 μM DFX, the number of cells in S phase increased in all three cell lines (n = 1)

Full size image

DFX induced apoptosis in pancreatic cancer cell lines

To further characterize the mechanisms of the antiproliferative activity of DFX, the pancreatic cancer cell lines BxPC-3, HPAF-II, and Panc 10.0 were incubated with either the vehicle control (PBS) or concentrations of 10, 50, or 100 μM of DFX for 72 h, and apoptosis was examined by flow cytometry using PI and Annexin V staining. The results are shown in Fig. 3a. The amount of live cells was defined as the number of cells negative for both Annexin V and PI. The amount of cells in early apoptosis was defined as cells positive for Annexin V only, whereas late apoptosis was defined as cells positive for both Annexin V and PI. The amount of necrotic cells was defined as the cells negative for Annexin V but positive for PI. The percentages of live, apoptotic, and necrotic cells are shown in Fig. 3b. Incubation with 50 or 100 μM DFX significantly decreased the number of live cells compared with control cells in all three cell lines. Moreover, incubation with 50 or 100 μM DFX typically increased the number of cells in late apoptosis in all three cell lines. Apoptosis was also examined by measuring the caspase 3/7 activity with a luminescence assay. The analyzed results are shown in Fig. 4. In all three cell lines, the caspase 3/7 activities were significantly higher in cells incubated with 100 μM of DFX compared with control cells. These results demonstrated that 50 and 100 μM DFX induced apoptosis in pancreatic cancer cells.

Fig. 3
figure 3

DFX induced apoptosis in pancreatic cancer cell lines. a BxPC-3, HPAF-II, and Panc 10.05 cells were incubated with the vehicle control (PBS) or DFX at 10, 50, or 100 μM for 72 h. DFX-treated BxPC-3, HPAF-II, and Panc 10.05 cells were stained with Annexin V/PI and examined by flow cytometry. b The percentages of live, apoptotic, and necrotic cells are presented as the mean ± SD (n = 3). *p <0.05, **p <0.01 vs. control

Full size image
Fig. 4
figure 4

DFX increased caspase 3/7 activity in pancreatic cancer cell lines. BxPC-3, HPAF-II, and Panc 10.05 cells were incubated with the vehicle control (PBS) or DFX at concentrations of 10, 50, or 100 μM for 48 h. Immediately after the incubation, caspase 3/7 activity was measured using a luminescence assay and corrected for cell viability determined using the MTS assay. The corrected caspase 3/7 activities of BxPC-3, HPAF-II, and Panc 10.05 cells incubated with DFX increased in a dose-dependent manner. The data are presented as the mean ± SD (n = 3). *p <0.05, **p <0.01 vs. control

Full size image

DFX inhibited the growth of human pancreatic cancer xenografts

Next, the antiproliferative activity of DFX against pancreatic cancer was assessed in vivo using BxPC-3 pancreatic cancer xenografts in BALB/c nude mice. As DFX is given to patients orally, we administered DFX as a saline suspension given orally in accordance with previous studies [22, 23]. DFX administered orally at 160 and 200 mg/kg (every second day, three treatments per week for 21 days) resulted in marked inhibition of tumor growth as determined by measurements of tumor volume and tumor weight (Fig. 5a, b, and c). After 21 days of oral treatment with the vehicle control (saline solution), the tumor xenografts reached an average volume of 674 ± 150 mm3. In contrast, the tumor volumes were significantly reduced to 327 ± 45 and 274 ± 67 mm3 in mice treated with 160 and 200 mg/kg DFX, respectively (Fig. 5a). At the end of the experiment, the tumors were excised and measured. The control tumors weighed 0.6 ± 0.2 g, whereas tumors treated with 160 and 200 mg/kg oral DFX weighed significantly less than the control tumors at 0.4 ± 0.04 and 0.3 ± 0.1 g, respectively (Fig. 5c). Furthermore, in the blood sample examinations, DFX administered orally at 160 and 200 mg/kg for 3 weeks significantly decreased serum levels of ferritin to 8.6 ± 1.5 and 9.8 ± 1.5 ng/ml, respectively, compared with mice that received vehicle alone (18.3 ± 1.9 ng/ml; Table 2). While DFX administered at 160 and 200 mg/kg inhibited tumor growth and decreased the serum levels of ferritin, the mice did not show body weight loss or altered serum biochemistry, with the exception of the serum levels of ferritin (Fig. 5d and Table 2). On the other hand, DFX administered at 120 mg/kg did not significantly inhibit tumor growth, compared with mice administered vehicle alone. Additionally, it is important to note that DFX administered at 120 mg/kg also failed to reduce the serum levels of ferritin in mice. These observations are consistent with immunohistochemical studies on tumor xenografts that performed semi-quantitative analyses of tumor sections. While tumors treated with 160 and 200 mg/kg oral DFX significantly reduced ferritin-H protein levels compared with tumors treated with the vehicle alone, tumors treated with 120 mg/kg oral DFX did not significantly decrease the ferritin-H protein levels compared with tumors treated with the vehicle alone (Fig. 6a and b). These data indicated that tumor growth could be suppressed when tumors were treated with a sufficient dose of DFX, which functions as an iron chelator.

Fig. 5
figure 5

Orally administered DFX markedly inhibited the growth of pancreatic cancer xenografts in nude mice. a DFX (160 and 200 mg/kg orally, given by gavage every second day, for a total of three treatments per week for 21 days) significantly inhibited the growth of human pancreatic cancer BxPC-3 xenografts in vivo. b The removed tumors were measured and processed for immunohistochemistry and genetic analyses. c The removed tumors from mice treated with 160 and 200 mg/kg oral DFX weighed significantly less than the control tumors. d The average weight of mice in each treatment group during the course of treatment

Full size image
Table 2 Serum indices from nude mice bearing a BxPC-3 xenograft that were treated orally by gavage with either the vehicle control or DFX (120, 160, or 200 mg/kg) every second day (three treatments per week) for 21 days
Full size table
Fig. 6
figure 6

Orally administered DFX reduced ferritin-H protein levels of removed tumors in immunohistochemical analyses. a Immunohistochemistry was performed on the removed tumors with antibody specific to ferritin-H. b The slides were scored for the percentage of positive cells (0 = 0–5, 1 = 6–25, 2 = 26–50, 3 = 51–75 and 4 = 76–100 %) and intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong). The immunoreactivity score was calculated as the percentage of positive cells multiplied by the score for the staining intensity. The immunoreactivity scores of removed tumors treated orally with 160 and 200 mg/kg of DFX were significantly lower than that of control tumors. The data are presented as the mean ± SD (n = 5 mice per group). For statistical analysis, each treatment was compared with the control. *p <0.05, **p <0.01 vs. control

Full size image

DFX downregulated genes in the pancreatic adenocarcinoma signaling pathway

To investigate the genetic effect of DFX in pancreatic cancer, we examined gene expression alternations in the removed tumors exposed to DFX. From the results of the cancer xenograft experiments, we found that the tumors treated with 200 mg/kg oral DFX were suitable for examining gene expression alterations. Thus, three tumors were randomly chosen from the tumors treated with 200 mg/kg oral DFX, and another three tumors were randomly chosen from the control tumors. After the whole genome microarray analysis, a total of 2412 genes were recognized as differentially expressed with a significance cutoff of p <0.05. These genes were imported into the IPA, and pathway analyses were performed. The top canonical pathways are shown in Fig. 7a. Pancreatic adenocarcinoma signaling was identified as one of the top canonical pathways. This observation indicated that DFX strongly affected xenografted pancreatic cancer genetically. A heatmap of differently expressed genes included in pancreatic adenocarcinoma signaling is shown in Fig. 7c. Genes highlighted in red indicate upregulation versus the control tumors, while green indicates downregulation in the treated tumors. According to the heatmap, most genes in the pancreatic adenocarcinoma signaling pathway were downregulated by DFX. Specifically, transforming growth factor-ß1 (TGF- ß1) was strongly inhibited. The top upstream regulators are shown in Fig. 7b; TGF- ß1 was also a top upstream regulator. These data demonstrated that the antiproliferative activities of DFX were sustained genetically.

Fig. 7
figure 7

DFX downregulated the genes in pancreatic adenocarcinoma signaling. A total of six tumors, three tumors from mice treated with 200 mg/kg oral DFX, and three tumors from the controls, were chosen to examine gene expression alternation. A total of 2412 genes differentially expressed with a significance cutoff of p <0.05 were imported into the IPA. a Top canonical pathways by DFX treatment in the removed tumors. Pancreatic adenocarcinoma signaling was observed. b Top upstream regulators by DFX treatment in the removed tumors; TGF- ß1 was strongly inhibited. c A heatmap of differently expressed genes in the Pancreatic Adenocarcinoma Signaling pathway. Most of the genes were downregulated after DFX treatment

Full size image

Discussion

The antiproliferative activity of iron chelators was first demonstrated on leukemia in cell cultures and clinical trials [24, 25]. Then, the antiproliferative activity of iron chelators was demonstrated in solid tumors, including pancreatic cancer tumors, and in cell culture in recent studies [15, 26, 27]. DFO was the first commercially available iron chelator to be used for the treatment of iron-overload disease [28]. DFO has also been used for studies researching the antiproliferative activity of iron chelators in cell cultures and clinical trials [13–15, 25–27]. Although DFO exhibits antiproliferative activity, this chelator has serious limitations because it is not utilized by the body if administered orally and has a short serum half-life. DFO needs to be given parenterally (either subcutaneously or intravenous infusion) for long periods, typically 8–12 h per day, which has led to poor patient compliance. On the other hand, DFX, a recently identified iron chelator, can be administered orally once daily because it is orally active and has a long half-life of 7–18 h. DFX is currently used for the treatment of iron-overload disease and is considered an alternative to DFO [16]. The antiproliferative activity of DFX has been investigated in various cancers [22, 23, 29, 30]. However, there have previously been no studies of the effects of DFX in pancreatic cancer; this study is the first to elucidate the antiproliferative activity of DFX against pancreatic cancer cells.

We examined the in vitro antiproliferative activity of DFX using an MTS assay in three pancreatic cancer cell lines: BxPC-3, HPAF-II, and Panc 10.05. We observed a dose-dependent antiproliferative activity of DFX in pancreatic cancer cell lines, consistent with the results of previous studies in esophageal cancer cell lines [22] or lung cancer cell lines [23]. Although a number of studies have attempted to elucidate the anti-cancer mechanisms of iron chelators, their mechanisms are not well known [12]. Especially in pancreatic cancer, there have been few studies investigating the effect of iron chelators as anticancer agents [15]. To investigate the mechanisms of the antiproliferative activity of DFX, we examined the effects of DFX on the cell cycle and apoptosis in pancreatic cancer cell lines. We observed that 10 μM DFX inhibited pancreatic cancer cell proliferation by arresting the cell cycle in the S phase, and 50 and 100 μM DFX inhibited pancreatic cancer cell proliferation by inducing apoptosis. These anti-cancer mechanisms of DFX are consistent with those found in previous reports for most iron chelators [15, 31, 32].

We next assessed the ability of DFX to inhibit pancreatic cancer growth in vivo using a murine xenograft model. We administered DFX at doses of 120, 160, and 200 mg/kg every second day, totaling three treatments per week for 3 weeks. The doses of 160 and 200 mg/kg of DFX successfully inhibited tumor growth and decreased serum and tumor levels of ferritin. Initially, we attempted to administer DFX at doses of 20–40 mg/kg every second day, for three treatments per week for 3 weeks because a 20 mg/kg per day regimen is considered suitable in patients with iron overload [33]. However, in nude mice, 20–40 mg/kg DFX did not inhibit tumor growth or reduce serum levels of ferritin (data not shown). In fact, even a dose of 120 mg/kg of DFX failed to significantly suppress either tumor growth or serum and tumor ferritin levels. The 3-week experiment may have been too short to assess the effects of a normal dose of DFX in this xenograft model. However, it is important to note that decreased serum and tumor levels of ferritin were observed in the mice that received 160 or 200 mg/kg doses of DFX administration, and the xenografted tumors were markedly suppressed. Furthermore, no serious effects on body weight and biological indices were observed. A previous in vivo study using DFX also demonstrated the importance of iron depletion in the xenografted tumor for cancer therapy [22]. According to our study, we believe that DFX demonstrates antiproliferative activity by decreasing serum levels of ferritin, which is reflected as iron depletion in the tumor.

To assess the genetic effects of DFX for pancreatic cancer, we conducted microarray analysis using in vivo samples. Most genes included in pancreatic adenocarcinoma signaling, especially TBF- ß1, were downregulated by DFX administration. A previous study revealed that TGF- ß overexpression is associated with early recurrence following resection and decreased survival in patients with pancreatic cancer [34]. TGF- ß1 also plays pivotal roles in driving epithelial-mesenchymal transition (EMT) in the pathogenesis of pancreatic cancer [35, 36]. In fact, the TGF- ß signaling inhibitor displays antiproliferative activity for pancreatic cancer [37]. A recent review article also demonstrated that iron chelators can target several pathways, including the TBF- ß pathway, to subsequently inhibit cellular proliferation, EMT and metastasis [38]. This evidence, combined with the results of our microarray analysis, indicates that DFX works as anticancer agent by suppressing TGF- ß signaling.

Conclusions

We first elucidated that DFX has potential as a therapeutic agent for pancreatic cancer. We demonstrated that DFX inhibits pancreatic cancer cell growth by arresting the cell cycle and inducing apoptosis. Furthermore, DFX inhibited pancreatic cancer growth in vivo in a murine xenograft model. Genetically, TGF- ß1 plays a key role in the effect of DFX against pancreatic cancer. Because DFX is a commercially available oral iron chelator, its clinical application can be considerable. While further extensive studies are required, the DFX treatment strategy can be considered a novel effective and safe pancreatic cancer therapy in the near future.

Abbreviations

DFO:

Deferoxamine

DFX:

Deferasirox

EMT:

Epithelial-mesenchymal transition

IPA:

Ingenuity pathway analysis

MTS:

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt

PBS:

Phosphate-buffered saline

PI:

Propidium iodide

TGF- ß:

Transforming growth factor-ß

References

  1. Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, et al. Japan pancreatic cancer registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012;41:985–92.

    Article  PubMed  Google Scholar 

  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

    Article  CAS  PubMed  Google Scholar 

  3. Magee CJ, Ghaneh P, Neoptolemos JP. Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol. 2002;16:435–55.

    Article  PubMed  Google Scholar 

  4. SEER: Surveillance, Epidemiology, and End Results Program. Cancer statistics review, 1975–2012. National Cancer Institute. 2015. http://seer.cancer.gov/archive/csr/1975_2012/. Accessed 18 Nov 2015.

  5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, pancreatic adenocarcinoma. National Comprehensive Cancer Network. 2015. https://www.nccn.org/. Accessed 3 June 2015.

  6. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

    Article  CAS  PubMed  Google Scholar 

  7. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548–54.

    Article  Google Scholar 

  8. Crichton R. Iron metabolism: from molecular mechanisms to clinical consequences. Hoboken: Wiley; 2009.

    Book  Google Scholar 

  9. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res. 2006;12:6876–83.

    Article  CAS  PubMed  Google Scholar 

  10. Kicic A, Chua AC, Baker E. Effect of iron chelators on proliferation and iron uptake in hepatoma cells. Cancer. 2001;92:3093–110.

    Article  CAS  PubMed  Google Scholar 

  11. Yu Y, Gutierrez E, Kovacevic Z, Saletta F, Obeidy P, Suryo Rahmanto Y, et al. Iron chelators for the treatment of cancer. Curr Med Chem. 2012;19:2689–702.

    Article  CAS  PubMed  Google Scholar 

  12. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13:342–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Sakaida I, Hironaka K, Uchida K, Okita K. Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats. Dig Dis Sci. 1999;44:560–9.

    Article  CAS  PubMed  Google Scholar 

  14. Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med. 2011;365:576–8.

    Article  CAS  PubMed  Google Scholar 

  15. Kovacevic Z, Chikhani S, Lovejoy DB, Richardson DR. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol. 2011;80:598–609.

    Article  CAS  PubMed  Google Scholar 

  16. Cappellini MD, Taher A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol. 2009;122:165–73.

    Article  CAS  PubMed  Google Scholar 

  17. Bedford MR, Ford SJ, Horniblow RD, Iqbal TH, Tselepis C. Iron chelation in the treatment of cancer: a new role for deferasirox? J Clin Pharmacol. 2013;53:885–91.

    Article  CAS  PubMed  Google Scholar 

  18. Boult J, Roberts K, Brookes MJ, Hughes S, Bury JP, Cross SS, et al. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res. 2008;14:379–87.

    Article  CAS  PubMed  Google Scholar 

  19. Di Martino E, Wild CP, Rotimi O, Darnton JS, Olliver RJ, Hardie LJ. IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett’s oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk. Biomarkers. 2006;11:547–61.

    Article  PubMed  Google Scholar 

  20. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. BioInformatics. 2003;19:185–93.

    Article  CAS  PubMed  Google Scholar 

  21. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ford SJ, Obeidy P, Lovejoy DB, Bedford M, Nichols L, Chadwick C, et al. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br J Pharmacol. 2013;168:1316–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol. 2013;83:179–90.

    Article  CAS  PubMed  Google Scholar 

  24. Kontoghiorghes GJ, Piga A, Hoffbrand AV. Cytotoxic and DNA-inhibitory effects of iron chelators on human leukaemic cell lines. Hematol Oncol. 1986;4:195–204.

    Article  CAS  PubMed  Google Scholar 

  25. Estrov Z, Tawa A, Wang XH, Dubé ID, Sulh H, Cohen A, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood. 1987;69:757–61.

    CAS  PubMed  Google Scholar 

  26. Brard L, Granai CO, Swamy N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol. 2006;100:116–27.

    Article  CAS  PubMed  Google Scholar 

  27. Hoke EM, Maylock CA, Shacter E. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic Biol Med. 2005;39:403–11.

    Article  CAS  PubMed  Google Scholar 

  28. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739–61.

    CAS  PubMed  Google Scholar 

  29. Lescoat G, Chantrel-Groussard K, Pasdeloup N, Nick H, Brissot P, Gaboriau F. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif. 2007;40:755–67.

    Article  CAS  PubMed  Google Scholar 

  30. Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci. 2009;100:970–7.

    Article  CAS  PubMed  Google Scholar 

  31. Jin H, Xu Z, Li D, Huang J. Antiproliferative activity and therapeutic implications of potassium tris(4-methyl-1-pyrazolyl) borohydride in hepatocellular carcinoma. Chem Biol Interact. 2014;213:69–76.

    Article  CAS  PubMed  Google Scholar 

  32. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle. 2007;6:1982–94.

    Article  CAS  PubMed  Google Scholar 

  33. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Séchaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597–602.

    Article  CAS  PubMed  Google Scholar 

  34. Friess H, Yamanaka Y, Büchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterol. 1993;105:1846–56.

    Article  CAS  Google Scholar 

  35. Yin T, Wang C, Liu T, Zhao G, Zhou F. Implication of EMT induced by TGF-beta1 in pancreatic cancer. J Huazhong Univ Sci Technolog Med Sci. 2006;26:700–2.

    Article  CAS  PubMed  Google Scholar 

  36. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 2001;61:4222–8.

    CAS  PubMed  Google Scholar 

  37. Lou C, Zhang F, Yang M, Zhao J, Zeng W, Fang X, et al. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS ONE. 2012;7:e50956.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lui GY, Kovacevic Z, Richardson V, Merlot AM, Kalinowski DS, Richardson DR. Targeting cancer by binding iron: dissecting cellular signaling pathways. Oncotarget. 2015;6:18748–79.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Not applicable.

Funding

This study was supported by the Strategic Research Promotion Program from Yamaguchi University, the Translational Research Program from Yamaguchi University Hospital, and the Pancreatic Disease Research Award from the Pancreas Research Foundation of Japan.

Availability of data and materials

The microarray data have been deposited in the NCBI’s Gene Expression Omnibus (GEO) under GEO series accession no. GSE81363.

Authors’ contributions

HH and TT drafted the manuscript. SK and TY designed the study. SS, TM, KF, and NY acquired and analyzed the study data. IS approved the final manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interest.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Animal care was performed in accordance with the animal ethics requirements of Yamaguchi University School of Medicine, and the experimental protocol was approved (approval ID 21-035).

Author information

Author notes

    Authors and Affiliations

    1. Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan

      Hirofumi Harima, Seiji Kaino, Taro Takami, Shuhei Shinoda, Toshihiko Matsumoto, Koichi Fujisawa, Naoki Yamamoto & Isao Sakaida

    2. Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan

      Toshihiko Matsumoto & Takahiro Yamasaki

    Authors
    1. Hirofumi Harima
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Seiji Kaino
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Taro Takami
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Shuhei Shinoda
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Toshihiko Matsumoto
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Koichi Fujisawa
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Naoki Yamamoto
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Takahiro Yamasaki
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Isao Sakaida
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Seiji Kaino.

    Rights and permissions

    Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Harima, H., Kaino, S., Takami, T. et al. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. BMC Cancer 16, 702 (2016). https://doi.org/10.1186/s12885-016-2744-9

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1186/s12885-016-2744-9

    Keywords

    BMC Cancer

    ISSN: 1471-2407

    Contact us